Bob

Newsletters

The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer

[Frontiers in Oncology] Scientists review researches on the role of feedback loops in the progression of pancreatic cancer, and summarize the connection between feedback loops and several signaling pathways in pancreatic cancer, as well as recent advances in the intervention of feedback loops in pancreatic cancer treatment.

BC Researchers Launching Clinical Trial for First Genetically Engineered Stem Cell-Based Therapy for Type 1 Diabetes

[University of British Columbia] Researchers from the UBC Faculty of Medicine and Vancouver Coastal Health have received $1 million from Canada’s Stem Cell Network to conduct research and a clinical trial for one of the world’s first genetically engineered cell replacement therapies for type 1 diabetes.

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

[NexImmune, Inc.] NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

Survival Outcomes of Apalutamide as a Starting Treatment: Impact in Real-World Patients With Metastatic Hormone Sensitive Prostate Cancer (OASIS)

[Prostate Cancer and Prostatic Diseases] Scientists evaluated the impact of upfront therapy for metastatic hormone-sensitive prostate cancer on outcomes in real-world clinical practice in the United States.

A TBX2-Driven Signaling Switch From Androgen Receptor to Glucocorticoid Receptor Confers Therapeutic Resistance in Prostate Cancer

[Oncogene] Using human prostate cancer and CRPC cell line models, scientists demonstrated that TBX2 downregulated androgen receptor and upregulated glucocorticoid receptor through direct transcriptional regulation.

Radiotherapy-Resistant Prostate Cancer Cells Escape Immune Checkpoint Blockade through the Senescence-Related Ataxia Telangiectasia and Rad3-Related Protein

[Cancer Communications] Scientists identified a subset of prostate cancer cells that exhibited resistance to radiotherapy, characterized by a reduced antigen presentation capability, which enhanced their ability to evade immune detection and resist cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade.

All Articles by Author:

Bob

Popular